EGFR mutation testing

EGFR mutation testing in non-small cell lung cancer (NSCLC)

The epidermal growth factor receptor, EGFR, sits on the cell surface and its activation leads to signalling through the MAPK pathway. This can, in turn, lead to an increase in a number of cellular processes relevant to the growth and spread of cancer cells. The genes and proteins within this pathway are targets for anti-cancer therapies such as anti-EGFR TKIs (tyrosine kinase inhibitors), which are often prescribed in cases of lung cancer.

Activating, gain of function, mutations in EGFR are found in approximately 10% of all NSCLC tumours. Anti-EGFR TKIs such as Gefitinib (IressaTM) and Erlotinib (TarcevaTM), inhibit EGFR protein function, disrupting the EGFR signalling pathway and removing the stimulus for cancer cell growth. Tumours where these growth-promoting mutations are present will likely respond to treatment. Other mutations in exon 20 of the EGFR gene can confer resistance and indicate a likely lack of response to these drugs.

It is therefore important to understand the nature of any mutation detected in order to ensure appropriate treatment. The NewGene EGFR assay covers all of the mutations related to drug sensitivity.

Contact us

NewGene Limited
Bioscience Building
International Centre for Life
Newcastle upon Tyne
NE1 4EP, UK

Tel: +44 (0)191 242 1923
Fax: +44 (0)191 241 8799
Email: info@newgene.org.uk

Click here for location map

Mon – Fri 08:30 to 17:00, closed Bank Holidays

An ISO 15189 accredited Medical Laboratory company

NewGene Limited | Company Number: 06735445

Technology Partners

Agilent Technologies

Agena Bioscience

Illumina

Sophia Genetics

Qiagen

Promega

Enquiry form